1 PREFACE
1.1. Scope of the Report
1.2 Research Methodology
1.3. Chapter Outlines
3 INTRODUCTION
3.1. An Overview of Depression and Depressive Disorders
3.2. Signs and Symptoms of Depression
3.3. Types of Depression
3.4. Epidemiology of Depression
3.5. Causes of Depression
3.6. Diagnosis of Depression
3.7. Current Treatment Paradigms
3.7.1. Pharmacological Treatment
3.7.2. Psychological Treatment
3.7.3. Other Treatments
3.8. Innovative Therapeutic Strategies
3.9. Future Perspectives
4 PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS
4.1. Chapter Overview
4.2. Depressive Disorders: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Depressive Disorder
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Type of Molecules
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Drug and Drug Class
4.2.8. Major Depressive Disorder
4.2.8.1. Analysis by Phase of Development
4.2.8.2. Analysis by Route of Administration
4.2.8.3. Analysis by Dosing Frequency
4.2.8.4. Key Players
4.2.9. Bipolar Disorder / Bipolar Depression
4.2.9.1. Analysis by Phase of Development
4.2.9.2. Analysis by Route of Administration
4.2.9.3. Analysis by Dosing Frequency
4.2.9.4. Key Players
4.2.10. Treatment-Resistant Depression
4.2.10.1. Analysis by Phase of Development
4.2.10.2. Analysis by Route of Administration
4.2.10.3. Analysis by Dosing Frequency
4.2.10.4. Key Players
4.2.11. Postpartum Depression and Depression (Type Unknown)
4.2.11.1. Analysis by Phase of Development
4.2.11.2. Analysis by Route of Administration
4.2.11.3. Analysis by Dosing Frequency
4.2.11.4. Key Players
4.2.12 Grid Analysis: Distribution by Phase of Development, Type of Depressive Disorder and Type of Drug
4.3. Depressive Disorders: List of Drug Developers
4.3.1. Analysis by Year of Establishment of Developers
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location of Developers
4.3.4 Analysis by Type of Depressive Disorder
4.3.5. Key Developers
4.3.6. Grid Analysis: Distribution by Location of Developer, Company Size and Type of Depressive Disorder
4.4 Other Novel Ways to Treat Depression
4.4.1. Role of Neurostimulation Devices
4.4.2. Role of Microbiome Therapeutics
5 CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
5.1. Chapter Overview
5.2. Depressive Disorders: Discontinued Drugs
5.2.1. Analysis by Year of Discontinuation
5.2.2. Analysis by Phase of Discontinuation
5.2.3. Analysis by Mechanism of Action
5.2.4. Analysis by Type of Depressive Disorder
5.2.5. Key Players
5.2.6. Analysis by Reason for Discontinuation
5.3. Depressive Disorders: Discontinued Clinical Trials
5.3.1. Year-wise Trend of Discontinued Trials
5.3.2. Analysis of Discontinued Clinical Trials by Phase of Development
5.3.3. Analysis of Discontinued Clinical Trials by Sponsor / Collaborator
5.3.4. Analysis of Discontinued Clinical Trials by Geography
5.3.5. Analysis of Discontinued Clinical Trials by Reason of Discontinuation
5.4. Concluding Remarks
6 PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Depressive Disorders: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnerships
6.3.2. Analysis by Type of Partnership
6.3.3 Analysis by Type and Year pf Partnership
6.3.4. Analysis by Area of Focus
6.3.5. Analysis by Type of Depressive Disorder
6.3.6. Regional Analysis
6.3.6.1. Local and International Agreements
6.3.6.2. Intercontinental and Intracontinental Agreements
6.3.7. Most Active Players: Analysis by Number of Partnerships
6.3.8. Big Pharma Players
7 FUNDING AND INVESTMENT ANALYSIS
7.1. Chapter Overview
7.2. Types of Funding
7.3. Depressive Disorders: Funding and Investment Analysis
7.3.1. Analysis by Number of Instances
7.3.2. Analysis by Amount Invested
7.3.3. High Value Deals: Analysis by Year
7.3.4. Analysis by Type of Funding
7.3.5 Analysis by Number of Funding Instances across Different Therapeutic Areas
7.3.6. Most Active Players
7.3.7. Most Active Investors
7.4. Concluding Remarks
8 CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Depressive Disorders: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Recruitment Status
8.3.4. Analysis by Type of Sponsor / Collaborator
8.3.5. Analysis by Type of Depressive Disorder
8.3.6. Analysis by Type of Drug Class
8.3.7. Most Active Players
8.3.8. Analysis by Number of Clinical Trials and Geography
8.3.9. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
8.3.10. Analysis by Number of Clinical Trials, Type of Depressive Disorder and Geography
8.3.11. Analysis by Number of Clinical Trials, Type of Depressive Disorder, Trial Phase and Geography
8.3.12. Analysis by Number of Clinical Trials, Type of Drug Class and Geography
8.3.13. Analysis by Number of Clinical Trials, Type of Drug Class, Trial Phase and Geography
8.3.14. Analysis by Enrolled Patient Population and Geography
8.3.15. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
8.3.16. Analysis by Enrolled Patient Population, Type of Depressive Disorder and Geography
8.3.17. Analysis by Enrolled Patient Population, Type of Depressive Disorder, Trial Phase and Geography
8.3.18. Analysis by Enrolled Patient Population, Type of Drug Class and Geography
8.3.19. Analysis by Enrolled Patient Population, Type of Drug Class, Trial Phase and Geography
8.4. Concluding Remarks
8.4.1. Emerging Molecules to Watch
8.4.2. Most Important Trials to Watch
9 CLINICAL TRIAL ENDPOINTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Overview of Most Common Primary Endpoints
9.4. Primary Endpoints Evaluated for Major Depressive Disorder: Comparative Analysis of Late-Stage Drugs
9.5. Primary Endpoints Evaluated for Bipolar Disorder: Comparative Analysis of Late-Stage Drugs
9.6. Primary Endpoints Evaluated for Other Types of Depressive Disorder: Comparative Analysis of Late-Stage Drugs
10 CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.2.1. Assumptions and Key Parameters
10.3. Clinical and Commercial Attractiveness Analysis: Depressive Disorders
10.3.1. Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
10.3.2. Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
10.3.3. Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder
11 KEY COMMERCIALIZATION STRATEGIES
11.1. Chapter Overview
11.2. Successful Drug Launch Strategy: ROOTS Framework
11.3. Successful Drug Launch Strategy: Product Differentiation
11.4. Commercialization Strategies Adopted Based on Development Stage of Product
11.5. Approved Molecules for Treating Depressive Disorders
11.5.1. Abilify Mycite®
11.5.2. Abilify Maintena®
11.5.3. Rexulti®
11.5.4. Vraylar ®
11.5.5. Trintellix®
11.5.6. Fetzima®
11.5.7. Latuda®
11.5.8. Viibryd®
11.6. Key Commercialization Strategies Adopted by the Companies Focused on Depressive Disorders
11.6.1. Strategies Adopted Before the Approval of Drug
11.6.1.1. Participation in Global Events
11.6.2. Strategies Adopted During the Launch of Drug
11.6.2.1. Collaboration with Internal Stakeholders and Pharmaceutical Firms
11.6.2.2. Awareness through Product Websites
11.6.2.3. Direct to Consumer (DTC) Advertisements
11.6.3. Strategies Adopted Post Drug Launch / Near Patent Expiry of Drug
11.6.3.1. Approval of Drug in Multiple Geographies
11.6.3.2. Approval of Drug for Multiple Indications
11.7. Concluding Remarks
12 DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS
12.1. Chapter Overview
12.2. An Overview on Digital Therapeutics
12.3. Development and Commercialization Pathway for Digital Therapeutics
12.3.1. Discovery and Preclinical Research
12.3.2. Clinical Trials and Validation
12.3.3. Engaging Insurance Providers / Payers
12.3.4. Distribution and Marketing
12.4. Digital Therapeutics for Depressive Disorders
12.4.1. Standalone Software Applications
12.4.2. Personal Coaching
12.4.3. AI Support
12.4.4. Gaming Solutions
12.5 Concluding Remarks
13 CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
15 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 1.1 Depressive Disorders: Scope and Competitive Insights
Figure 3.1 Depression: Key Facts
Figure 3.2 Depression: Common Signs and Symptoms
Figure 3.3 Prevalence of Depression in Major Geographical Regions
Figure 3.4 Prevalence of Depression in Major Geographical Regions by Gender
Figure 3.5 Global Prevalence of Depression: Distribution by Gender and Age Groups
Figure 3.6 Prevalence of Various Types of Depression in the US
Figure 3.7 Causes of Depression
Figure 4.1 Depressive Disorders: Distribution by Phase of Development
Figure 4.2 Depressive Disorders: Distribution by Type of Depressive Disorder
Figure 4.3 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Figure 4.4 Depressive Disorders: Distribution by Type of Therapy
Figure 4.5 Depressive Disorders: Distribution by Type of Molecule
Figure 4.6 Depressive Disorders: Distribution by Route of Administration
Figure 4.7 Depressive Disorders: Distribution by Dosing Frequency
Figure 4.8 Depressive Disorders: Distribution by Type of Drug and Drug Class
Figure 4.9 Major Depressive Disorder: Distribution by Phase of Development
Figure 4.10 Major Depressive Disorder: Distribution by Route of Administration
Figure 4.11 Major Depressive Disorder: Distribution by Dosing Frequency
Figure 4.12 Major Depressive Disorder: Key Players
Figure 4.13 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Figure 4.14 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Figure 4.15 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Figure 4.16 Bipolar Disorder / Bipolar Depression: Key Players
Figure 4.17 Treatment-Resistant Depression: Distribution by Phase of Development
Figure 4.18 Treatment-Resistant Depression: Distribution by Route of Administration
Figure 4.19 Treatment-Resistant Depression: Distribution by Dosing Frequency
Figure 4.20 Treatment-Resistant Depression: Key Players
Figure 4.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Figure 4.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Figure 4.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Figure 4.24 Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Depressive Disorder and Type of Drug
Figure 4.25 Depressive Disorders: Distribution by Year of Establishment of Developer
Figure 4.26 Depressive Disorders: Distribution by Size of Developer (Employee Count)
Figure 4.27 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Figure 4.28 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Figure 4.29 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Figure 4.30 Depressive Disorders: Leading Players
Figure 4.31 Grid Analysis: Distribution by Location of Developer, Company Size (Employee Count) and Type of Depressive Disorder
Figure 5.1 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Figure 5.2 Failure Analysis: Distribution by Phase of Discontinuation
Figure 5.3 Failure Analysis: Distribution by Mechanism of Action
Figure 5.4 Failure Analysis: Distribution by Type of Depressive Disorder
Figure 5.5 Failure Analysis: Key Players
Figure 5.6 Failure Analysis: Distribution by Reason of Discontinuation
Figure 5.7 Failure Analysis: Relative Distribution by Reasons of Discontinuation and Phase of Development
Figure 5.8 Failure Analysis: Year-wise Distribution of Discontinued Trials
Figure 5.9 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Figure 5.10 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Figure 5.11 Failure Analysis: Distribution of Discontinued Trials by Geography
Figure 5.12 Failure Analysis: Distribution of Discontinued Trials by Year of Discontinuation and Geography
Figure 5.13 Failure Analysis: Distribution of Discontinued Trials by Reason of Discontinuation
Figure 5.14 Bubble Analysis: Distribution of Discontinued Trials by Year of Discontinuation, Reason of Discontinuation and Phase of Development
Figure 6.1 Partnerships and Collaborations: Cumulative Trend of Activity, by Year, 2012-2019
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Area of Focus
Figure 6.5 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 6.8 Partnerships and Collaborations: Most Active Players
Figure 6.9 Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
Figure 7.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2010-2019
Figure 7.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Figure 7.3 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2010-2019 (USD Million)
Figure 7.4 Funding and Investment Analysis: Average Amount Invested per Year (USD Million), 2010-2019
Figure 7.5 Funding and Investment Analysis: High Value Deals (USD Million), 2010-2019
Figure 7.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Figure 7.7 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019 (USD Million)
Figure 7.8 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2010-2014 and Post 2014
Figure 7.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2010-2014 and Post 2014 (USD Million)
Figure 7.10 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Figure 7.11 Funding and Investment Analysis: Most Active Players
Figure 7.12 Funding and Investment Analysis: Key Investors
Figure 7.11 Funding and Investment Summary, 2010-2019 (USD Million)
Figure 8.1 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year, 2001-2019
Figure 8.2 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography, 2001-2019
Figure 8.3 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year, 2001-2019
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruitment Status
Figure 8.8 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Drug Class
Figure 8.10 Clinical Trials Analysis: Most Active Industry and Non-Industry Players in Terms of Number of Trials Conducted
Figure 8.11 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.12 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Recruitment Status and Geography
Figure 8.13 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Depressive Disorder and Geography
Figure 8.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Drug Class and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Mechanism of Action and Geography
Figure 8.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 8.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Recruitment Status and Geography
Figure 8.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Depressive Disorder and Geography
Figure 8.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Drug Class and Geography
Figure 8.22 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Mechanism of Action and Geography
Figure 10.1 Clinical Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Depressive Disorders
Figure 10.2 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Major Depressive Disorder
Figure 10.3 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Bipolar Disorder / Bipolar Depression
Figure 10.4 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Other Depressive Disorders
Figure 11.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.2 Successful Drug Launch Strategy: Product Differentiation
Figure 11.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 11.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Depressive Disorders
Figure 11.5 Participation in Global Events: Historical Timeline
Figure 11.6 Approved Drugs for Depressive Disorders: Promotional Activities through Product Websites
Figure 11.7 Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 11.8 Approval of Drugs for Multiple Indications: Historical Timeline
Figure 12.1 Prescription Digital Therapeutics: Process Map
Figure 12.2 Digital Therapeutics: Google Trends (2008-2018)
LIST OF TABLES
Table 3.1 List of FDA Approved Antidepressants
Table 4.1 Depressive Disorders: Marketed and Development Pipeline
Table 4.2 Depressive Disorders: Information on Special Designations
Table 4.3 Depressive Disorders: Information on Site of Drug Administration
Table 4.4 Depressive Disorders: Information on Drug Type, Drug Class and Mechanism of Action
Table 4.5 Depressive Disorders: Developer Overview
Table 4.6 List of Neurostimulation Devices (Invasive) for Depression
Table 4.7 List of Neurostimulation Devices (Non-Invasive) for Depression
Table 5.1 Depressive Disorders: Pipeline of Discontinued Drugs
Table 5.2 Depressive Disorders: List of Discontinued Clinical Trials
Table 5.3 Depressive Disorders: List of Discontinued Drugs (Unvalidated)
Table 6.1 Depressive Disorders: Partnerships and Collaborations, 2012-2019
Table 7.1 Depressive Disorders: Funding and Investments, 2010-2019
Table 7.2 Funding and Investment Analysis: Summary of Investments
Table 8.1 Clinical Trial Analysis: Emerging Molecules to Watch
Table 8.2 Clinical Trial Analysis: Most Important Trials to Watch
Table 9.1 Clinical Trial Endpoint Analysis: List of Drugs
Table 9.2 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Major Depressive Disorder
Table 9.3 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Bipolar Disorder / Bipolar Depression
Table 9.4 Clinical Trial Endpoint Analysis: Key Primary Endpoints Evaluated for Other Depressive Disorders
Table 11.1 Drug Snapshot: Abilify Mycite®
Table 11.2 Drug Snapshot: Abilify Maintena®
Table 11.3 Drug Snapshot: Rexulti®
Table 11.4 Drug Snapshot: Vraylar®
Table 11.5 Drug Snapshot: Trintellix®
Table 11.6 Drug Snapshot: Fetzima®
Table 11.7 Drug Snapshot: Latuda®
Table 11.8 Drug Snapshot: Viibryd®
Table 11.9 Patient Support Services on Product Websites of Drugs for Depressive Disorders: Comparative Analysis
Table 11.10 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 12.1 Digital Therapeutics for Depressive Disorders: List of Solutions
Table 13.1 Depressive Disorders: Summary of Competitive Insights
Table 14.1 Global Prevalence of Depression: Distribution by Gender and Age Groups
Table 14.2 Depressive Disorders: Distribution by Phase of Development
Table 14.3 Depressive Disorders: Distribution by Type of Depressive Disorder
Table 14.4 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Table 14.5 Depressive Disorders: Distribution by Type of Therapy
Table 14.6 Depressive Disorders: Distribution by Type of Molecules
Table 14.7 Depressive Disorders: Distribution by Route of Administration
Table 14.8 Depressive Disorders: Distribution by Dosing Frequency
Table 14.9 Depressive Disorders: Distribution by Type Drug and Drug Class
Table 14.10 Major Depressive Disorder: Distribution by Phase of Development
Table 14.11 Major Depressive Disorder: Distribution by Route of Administration
Table 14.12 Major Depressive Disorder: Distribution by Dosing Frequency
Table 14.13 Major Depressive Disorder: Key Players
Table 14.14 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Table 14.15 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Table 14.16 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Table 14.17 Bipolar Disorder / Bipolar Depression: Key Players
Table 14.18 Treatment-Resistant Depression: Distribution by Phase of Development
Table 14.19 Treatment-Resistant Depression: Distribution by Route of Administration
Table 14.20 Treatment-Resistant Depression: Distribution by Dosing Frequency
Table 14.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Table 14.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Table 14.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Table 14.24 Depressive Disorders: Distribution by Year of Establishment of Developer
Table 14.25 Depressive Disorders: Distribution by Company Size (Employee Count)
Table 14.26 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Table 14.27 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Table 14.28 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Table 14.29 Depressive Disorders: Key Players
Table 14.30 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Table 14.31 Failure Analysis: Distribution by Phase of Discontinuation
Table 14.32 Failure Analysis: Distribution by Mechanism of Action
Table 14.33 Failure Analysis: Distribution by Type of Depressive Disorder
Table 14.34 Failure Analysis: Key Players
Table 14.35 Failure Analysis: Distribution by Reason of Discontinuation
Table 14.36 Failure Analysis: Relative Distribution by Reasons of Discontinuation and Phase of Development
Table 14.37 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Table 14.38 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Table 14.39 Failure Analysis: Distribution of Discontinued Trials by Reason of Discontinuation
Table 14.40 Partnerships and Collaborations: Cumulative Trend of Activity, by Year, 2012-2019
Table 14.41 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.42 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Table 14.43 Partnerships and Collaborations: Distribution by Area of Focus
Table 14.44 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Table 14.45 Partnerships and Collaborations: Regional Distribution
Table 14.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 14.47 Partnerships and Collaborations: Most Active Players
Table 14.48 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Table 14.49 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2010-2019 (USD Million)
Table 14.50 Funding and Investments: Average Amount Invested per Year (USD Million), 2010-2019
Table 14.51 Funding and Investment Analysis: High Value Deals (USD Million), 2010-2019
Table 14.52 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Table 14.53 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019 (USD Million)
Table 14.54 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2010-2014 and Post 2014
Table 14.55 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2010-2014 and Post 2014 (USD Million)
Table 14.56 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Table 14.57 Funding and Investment Analysis: Most Active Players
Table 14.58 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year, 2001-2019
Table 14.59 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography, 2001-2019
Table 14.60 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year, 2001-2019
Table 14.61 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 14.62 Clinical Trial Analysis: Distribution by Trial Status
Table 14.63 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.64 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruiting Status
Table 14.65 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year
Table 14.66 Clinical Trial Analysis: Distribution by Type of Drug Class
Table 14.67 Clinical Trials Analysis: Most Active Industry and Non-Industry Players in Terms of Number of Trials Conducted
